
Dexcom receives FDA warning letter
Dexcom (Nasdaq: DXCM) + faces regulatory scrutiny in the U.S. following inspections of sites in California and Arizona. Our sister site, Drug Delivery Business News, reports today that the company received a warning letter from the FDA. The letter followed …